Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：ABC294640治疗晚期实体肿瘤患者的Ⅰ期临床试验结果

2017-08-24 MedSci MedSci原创

晚期实体肿瘤ABC294640临床试验
关注

鞘氨醇激酶（SK1，SK2）通过调节有丝分裂及S1P影响肿瘤生长。ABC294640是第一种口服的SK2抑制剂。CLIN CANCER RES近期发表了一篇文章，报道了ABC294640治疗实体肿瘤的Ⅰ期临床试验结果。

鞘氨醇激酶（SK1，SK2）通过调节有丝分裂及S1P影响肿瘤生长。ABC294640是第一种口服的SK2抑制剂。CLIN CANCER RES近期发表了一篇文章，报道了ABC294640治疗实体肿瘤的Ⅰ期临床试验结果。晚期实体肿瘤的患者接受剂量递增的口服ABC294640治疗，剂量水平为：250mg qd，250mg bid，500mg bid和750mg bid，周期28天。连续收集血样本测定ABC294640浓度。研究共纳入22例患者，21例接受了ABC294640治疗。最常见的药物相关毒性为恶心，呕吐及虚弱。750 mg bid的4例患者中，1例出现剂量限值3级恶心和呕吐，2例由于严重的药物相关毒性无法完成1个周期治疗。500mg bid水平为Ⅱ期试验的推荐剂量。ABC294640摄入后在12小时内会使S1P水平下降，24小时回到基线水平。1例胆管癌患者在250mg bid出现部分反应，为出现的最佳治疗效果，不同剂量水平的6例不同肿瘤患者出现病情稳定。文章最后认为，在500mg bid水平，ABC294640耐受性良好并达到生物学相关血浆浓度。血浆鞘脂水平的改变可以作为ABC29

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2088689, encodeId=c2302088689e4, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jul 12 21:31:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777062, encodeId=203c1e770629a, content=<a href='/topic/show?id=45ae1e1830' target=_blank style='color:#2F92EE;'>#ABC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1718, encryptionId=45ae1e1830, topicName=ABC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54039078223, createdName=cmj21wellington, createdTime=Tue Aug 07 09:31:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652796, encodeId=90171652e96f4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Mar 20 11:31:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754571, encodeId=bc2b1e545712a, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59822, encryptionId=627a5982254, topicName=晚期实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333936755048, createdName=30397616, createdTime=Mon May 07 22:31:00 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379145, encodeId=939513e9145ee, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Sat Aug 26 04:31:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424200, encodeId=6ba9142420011, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Aug 26 04:31:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236700, encodeId=ddca236e005a, content=希望能给患者带来更好的生存., beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4ib9DvJ86XtOw5PH8FicmNC2SQbYVgLXBxVWA2A4LlibcSyK7bCJHLVdX00iah2aM0XTEZ7SKtLb3ANw/0, createdBy=006d1709280, createdName=1de9c4fdm02(暂无匿称), createdTime=Thu Aug 24 15:21:59 CST 2017, time=2017-08-24, status=1, ipAttribution=)]
    2018-07-12 839640778

    #I期临床试验#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2088689, encodeId=c2302088689e4, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jul 12 21:31:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777062, encodeId=203c1e770629a, content=<a href='/topic/show?id=45ae1e1830' target=_blank style='color:#2F92EE;'>#ABC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1718, encryptionId=45ae1e1830, topicName=ABC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54039078223, createdName=cmj21wellington, createdTime=Tue Aug 07 09:31:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652796, encodeId=90171652e96f4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Mar 20 11:31:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754571, encodeId=bc2b1e545712a, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59822, encryptionId=627a5982254, topicName=晚期实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333936755048, createdName=30397616, createdTime=Mon May 07 22:31:00 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379145, encodeId=939513e9145ee, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Sat Aug 26 04:31:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424200, encodeId=6ba9142420011, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Aug 26 04:31:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236700, encodeId=ddca236e005a, content=希望能给患者带来更好的生存., beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4ib9DvJ86XtOw5PH8FicmNC2SQbYVgLXBxVWA2A4LlibcSyK7bCJHLVdX00iah2aM0XTEZ7SKtLb3ANw/0, createdBy=006d1709280, createdName=1de9c4fdm02(暂无匿称), createdTime=Thu Aug 24 15:21:59 CST 2017, time=2017-08-24, status=1, ipAttribution=)]
    2018-08-07 cmj21wellington

    #ABC#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2088689, encodeId=c2302088689e4, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jul 12 21:31:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777062, encodeId=203c1e770629a, content=<a href='/topic/show?id=45ae1e1830' target=_blank style='color:#2F92EE;'>#ABC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1718, encryptionId=45ae1e1830, topicName=ABC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54039078223, createdName=cmj21wellington, createdTime=Tue Aug 07 09:31:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652796, encodeId=90171652e96f4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Mar 20 11:31:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754571, encodeId=bc2b1e545712a, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59822, encryptionId=627a5982254, topicName=晚期实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333936755048, createdName=30397616, createdTime=Mon May 07 22:31:00 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379145, encodeId=939513e9145ee, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Sat Aug 26 04:31:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424200, encodeId=6ba9142420011, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Aug 26 04:31:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236700, encodeId=ddca236e005a, content=希望能给患者带来更好的生存., beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4ib9DvJ86XtOw5PH8FicmNC2SQbYVgLXBxVWA2A4LlibcSyK7bCJHLVdX00iah2aM0XTEZ7SKtLb3ANw/0, createdBy=006d1709280, createdName=1de9c4fdm02(暂无匿称), createdTime=Thu Aug 24 15:21:59 CST 2017, time=2017-08-24, status=1, ipAttribution=)]
    2018-03-20 医生2402

    #I期临床#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2088689, encodeId=c2302088689e4, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jul 12 21:31:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777062, encodeId=203c1e770629a, content=<a href='/topic/show?id=45ae1e1830' target=_blank style='color:#2F92EE;'>#ABC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1718, encryptionId=45ae1e1830, topicName=ABC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54039078223, createdName=cmj21wellington, createdTime=Tue Aug 07 09:31:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652796, encodeId=90171652e96f4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Mar 20 11:31:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754571, encodeId=bc2b1e545712a, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59822, encryptionId=627a5982254, topicName=晚期实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333936755048, createdName=30397616, createdTime=Mon May 07 22:31:00 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379145, encodeId=939513e9145ee, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Sat Aug 26 04:31:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424200, encodeId=6ba9142420011, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Aug 26 04:31:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236700, encodeId=ddca236e005a, content=希望能给患者带来更好的生存., beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4ib9DvJ86XtOw5PH8FicmNC2SQbYVgLXBxVWA2A4LlibcSyK7bCJHLVdX00iah2aM0XTEZ7SKtLb3ANw/0, createdBy=006d1709280, createdName=1de9c4fdm02(暂无匿称), createdTime=Thu Aug 24 15:21:59 CST 2017, time=2017-08-24, status=1, ipAttribution=)]
    2018-05-07 30397616

    #晚期实体肿瘤#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2088689, encodeId=c2302088689e4, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jul 12 21:31:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777062, encodeId=203c1e770629a, content=<a href='/topic/show?id=45ae1e1830' target=_blank style='color:#2F92EE;'>#ABC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1718, encryptionId=45ae1e1830, topicName=ABC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54039078223, createdName=cmj21wellington, createdTime=Tue Aug 07 09:31:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652796, encodeId=90171652e96f4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Mar 20 11:31:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754571, encodeId=bc2b1e545712a, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59822, encryptionId=627a5982254, topicName=晚期实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333936755048, createdName=30397616, createdTime=Mon May 07 22:31:00 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379145, encodeId=939513e9145ee, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Sat Aug 26 04:31:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424200, encodeId=6ba9142420011, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Aug 26 04:31:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236700, encodeId=ddca236e005a, content=希望能给患者带来更好的生存., beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4ib9DvJ86XtOw5PH8FicmNC2SQbYVgLXBxVWA2A4LlibcSyK7bCJHLVdX00iah2aM0XTEZ7SKtLb3ANw/0, createdBy=006d1709280, createdName=1de9c4fdm02(暂无匿称), createdTime=Thu Aug 24 15:21:59 CST 2017, time=2017-08-24, status=1, ipAttribution=)]
    2017-08-26 weiz

    #实体肿瘤#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2088689, encodeId=c2302088689e4, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jul 12 21:31:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777062, encodeId=203c1e770629a, content=<a href='/topic/show?id=45ae1e1830' target=_blank style='color:#2F92EE;'>#ABC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1718, encryptionId=45ae1e1830, topicName=ABC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54039078223, createdName=cmj21wellington, createdTime=Tue Aug 07 09:31:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652796, encodeId=90171652e96f4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Mar 20 11:31:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754571, encodeId=bc2b1e545712a, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59822, encryptionId=627a5982254, topicName=晚期实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333936755048, createdName=30397616, createdTime=Mon May 07 22:31:00 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379145, encodeId=939513e9145ee, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Sat Aug 26 04:31:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424200, encodeId=6ba9142420011, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Aug 26 04:31:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236700, encodeId=ddca236e005a, content=希望能给患者带来更好的生存., beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4ib9DvJ86XtOw5PH8FicmNC2SQbYVgLXBxVWA2A4LlibcSyK7bCJHLVdX00iah2aM0XTEZ7SKtLb3ANw/0, createdBy=006d1709280, createdName=1de9c4fdm02(暂无匿称), createdTime=Thu Aug 24 15:21:59 CST 2017, time=2017-08-24, status=1, ipAttribution=)]
    2017-08-26 lanyan20020087

    #肿瘤患者#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2088689, encodeId=c2302088689e4, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jul 12 21:31:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777062, encodeId=203c1e770629a, content=<a href='/topic/show?id=45ae1e1830' target=_blank style='color:#2F92EE;'>#ABC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1718, encryptionId=45ae1e1830, topicName=ABC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54039078223, createdName=cmj21wellington, createdTime=Tue Aug 07 09:31:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652796, encodeId=90171652e96f4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Mar 20 11:31:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754571, encodeId=bc2b1e545712a, content=<a href='/topic/show?id=627a5982254' target=_blank style='color:#2F92EE;'>#晚期实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59822, encryptionId=627a5982254, topicName=晚期实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333936755048, createdName=30397616, createdTime=Mon May 07 22:31:00 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379145, encodeId=939513e9145ee, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Sat Aug 26 04:31:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424200, encodeId=6ba9142420011, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Aug 26 04:31:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236700, encodeId=ddca236e005a, content=希望能给患者带来更好的生存., beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4ib9DvJ86XtOw5PH8FicmNC2SQbYVgLXBxVWA2A4LlibcSyK7bCJHLVdX00iah2aM0XTEZ7SKtLb3ANw/0, createdBy=006d1709280, createdName=1de9c4fdm02(暂无匿称), createdTime=Thu Aug 24 15:21:59 CST 2017, time=2017-08-24, status=1, ipAttribution=)]
    2017-08-24 1de9c4fdm02(暂无匿称)

    希望能给患者带来更好的生存.

    0

相关资讯

CLIN CANCER RES：IDO1口服抑制剂治疗晚期实体肿瘤

IDO1催化色氨酸降解为NFK。IDO1在许多实体肿瘤中过表达，促使肿瘤逃逸机体免疫监视。CLIN CANCER RES近期发表了一篇文章，报道了IDO1选择性抑制剂epacadostat（INCB024360）Ⅰ期临床试验结果。

Baidu
map
Baidu
map
Baidu
map